Education
About Us
Working with TipRanks
Follow Us
APONTIS PHARMA AG (DE:APPH)
XETRA:APPH
Total Valuation
APONTIS PHARMA AG has a market cap or net worth of €94.77M. The enterprise value is €68.26M.
Market Cap€94.77M
Enterprise Value€68.26M
Share Statistics
APONTIS PHARMA AG has 8,500,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,500,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
APONTIS PHARMA AG’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 2.09%.
Return on Equity (ROE)0.02
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)2.09%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee353.78K
Profits Per Employee5.50K
Employee Count137
Asset Turnover1.09
Inventory Turnover3.80
Valuation Ratios
The current PE Ratio of APONTIS PHARMA AG is 113.30. APONTIS PHARMA AG’s PEG ratio is -1.06.
PE Ratio113.30
PS Ratio0.00
PB Ratio2.75
Price to Fair Value2.75
Price to FCF-16.29
Price to Operating Cash Flow-29.43
PEG Ratio-1.06
Income Statement
In the last 12 months, APONTIS PHARMA AG had revenue of 48.47M and earned 753.57K in profits. Earnings per share was 0.09.
Revenue48.47M
Gross Profit27.70M
Operating Income1.26M
Pretax Income1.15M
Net Income753.57K
EBITDA3.56M
Earnings Per Share (EPS)0.09
Cash Flow
In the last 12 months, operating cash flow was -7.34M and capital expenditures -2.63M, giving a free cash flow of -9.97M billion.
Operating Cash Flow-7.34M
Free Cash Flow-9.97M
Free Cash Flow per Share-1.17
Dividends & Yields
APONTIS PHARMA AG pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.13
52-Week Price Change34.99%
50-Day Moving Average11.32
200-Day Moving Average9.51
Relative Strength Index (RSI)46.76
Average Volume (3m)1.30K
Important Dates
APONTIS PHARMA AG upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
APONTIS PHARMA AG as a current ratio of 4.93, with Debt / Equity ratio of 0.00%
Current Ratio4.93
Quick Ratio3.78
Debt to Market Cap0.00
Net Debt to EBITDA-4.34
Interest Coverage Ratio7.44
Taxes
In the past 12 months, APONTIS PHARMA AG has paid 399.54K in taxes.
Income Tax399.54K
Effective Tax Rate0.35
Enterprise Valuation
APONTIS PHARMA AG EV to EBITDA ratio is 19.62, with an EV/FCF ratio of -13.34.
EV to Sales1.44
EV to EBITDA19.62
EV to Free Cash Flow-13.34
EV to Operating Cash Flow-24.11
Balance Sheet
APONTIS PHARMA AG has €16.16M in cash and marketable securities with €0.00 in debt, giving a net cash position of -€16.16M billion.
Cash & Marketable Securities€16.16M
Total Debt€0.00
Net Cash-€16.16M
Net Cash Per Share-€1.90
Tangible Book Value Per Share€1.57
Margins
Gross margin is 1.97%, with operating margin of 2.61%, and net profit margin of 1.55%.
Gross Margin1.97%
Operating Margin2.61%
Pretax Margin2.38%
Net Profit Margin1.55%
EBITDA Margin7.35%
EBIT Margin2.73%
Analyst Forecast
The average price target for APONTIS PHARMA AG is €10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target€10.00
Price Target Upside-10.31% Downside
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast31.12%
EPS Growth Forecast―